{"id":"lpv-rtv-pellets-and-azt-3tc-or-abc-3tc","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Lipid abnormalities"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Peripheral neuropathy (AZT-related)"},{"rate":null,"effect":"Anemia (AZT-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lopinavir/ritonavir (LPV/RTV) inhibits HIV protease, preventing the maturation of viral particles and reducing infectious virions. The nucleoside reverse transcriptase inhibitors (AZT/3TC or ABC/3TC) block reverse transcriptase, preventing conversion of viral RNA to DNA. Together, these agents provide synergistic suppression of HIV replication through complementary mechanisms. The pellet formulation is designed for pediatric administration.","oneSentence":"This combination therapy uses protease inhibitors (lopinavir/ritonavir) to block HIV protease, combined with nucleoside reverse transcriptase inhibitors (AZT/3TC or ABC/3TC) to inhibit viral replication at multiple steps.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:41.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in pediatric patients (pellet formulation)"}]},"trialDetails":[{"nctId":"NCT02346487","phase":"PHASE3","title":"Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2015-09","conditions":"HIV","enrollment":1003}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":271,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LPV/RTV pellets and AZT/3TC or ABC/3TC","genericName":"LPV/RTV pellets and AZT/3TC or ABC/3TC","companyName":"Drugs for Neglected Diseases","companyId":"drugs-for-neglected-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy uses protease inhibitors (lopinavir/ritonavir) to block HIV protease, combined with nucleoside reverse transcriptase inhibitors (AZT/3TC or ABC/3TC) to inhibit viral replication at multiple steps. Used for HIV-1 infection in pediatric patients (pellet formulation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}